14-Aug-2026
Assembly Biosciences GAAP EPS of -$0.20 beats by $0.45, revenue of $13.37M beats by $6.92M
Seeking Alpha News (Thu, 13-Aug 4:22 PM ET)
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Globe Newswire (Thu, 13-Aug 4:00 PM ET)
Assembly Biosciences Announces Upcoming Investor Conference Presentations
Globe Newswire (Thu, 28-May 4:05 PM ET)
Globe Newswire (Tue, 26-May 4:05 PM ET)
Globe Newswire (Fri, 22-May 7:05 AM ET)
Globe Newswire (Fri, 22-May 7:00 AM ET)
Market Chameleon (Fri, 20-Mar 5:59 AM ET)
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Assembly Biosciences trades on the NASDAQ stock market under the symbol ASMB.
As of August 14, 2026, ASMB stock price climbed to $32.95 with 552,595 million shares trading.
ASMB has a beta of 1.03, meaning it tends to be more sensitive to market movements. ASMB has a correlation of 0.05 to the broad based SPY ETF.
ASMB has a market cap of $652.98 million. This is considered a Small Cap stock.
Last quarter Assembly Biosciences reported $13 million in Revenue and -$.20 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.36.
In the last 3 years, ASMB traded as high as $39.71 and as low as $7.69.
The top ETF exchange traded funds that ASMB belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
ASMB has outperformed the market in the last year with a price return of +32.0% while the SPY ETF gained +21.5%. ASMB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.7% and +31.2%, respectively, while the SPY returned +4.0% and +3.9%, respectively.
ASMB support price is $28.71 and resistance is $31.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASMB shares will trade within this expected range on the day.